218 related articles for article (PubMed ID: 26200707)
1. What Will It Take to Cure HIV?
Ananworanich J
Top Antivir Med; 2015; 23(2):80-4. PubMed ID: 26200707
[TBL] [Abstract][Full Text] [Related]
2. HIV Infection: Advances Toward a Cure.
Douek DC
Top Antivir Med; 2018 Apr; 25(4):121-125. PubMed ID: 29689537
[TBL] [Abstract][Full Text] [Related]
3. Clinical Interventions in HIV Cure Research.
Rasmussen TA; Søgaard OS
Adv Exp Med Biol; 2018; 1075():285-318. PubMed ID: 30030798
[TBL] [Abstract][Full Text] [Related]
4. Advances toward a cure for HIV: getting beyond n=2.
Li J
Top Antivir Med; 2020 Jan; 27(4):91-95. PubMed ID: 32224499
[TBL] [Abstract][Full Text] [Related]
5. [HIV may be cured].
Kjær AS; Østergaard HB
Ugeskr Laeger; 2015 Apr; 177(17):. PubMed ID: 25922162
[TBL] [Abstract][Full Text] [Related]
6. Eliminating the latent HIV reservoir by reactivation strategies: advancing to clinical trials.
Rasmussen TA; Tolstrup M; Winckelmann A; Østergaard L; Søgaard OS
Hum Vaccin Immunother; 2013 Apr; 9(4):790-9. PubMed ID: 23563519
[TBL] [Abstract][Full Text] [Related]
7. [Therapeutic approaches targeting HIV reservoirs].
Cheret A
Virologie (Montrouge); 2019 Aug; 23(4):250-259. PubMed ID: 31414662
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic HIV vaccines and broadly neutralizing antibodies.
Sobieszczyk ME
Top Antivir Med; 2020 Jan; 27(4):97-101. PubMed ID: 32224500
[TBL] [Abstract][Full Text] [Related]
9. Kill: boosting HIV-specific immune responses.
Trautmann L
Curr Opin HIV AIDS; 2016 Jul; 11(4):409-16. PubMed ID: 27054280
[TBL] [Abstract][Full Text] [Related]
10. Current views on HIV-1 latency, persistence, and cure.
Melkova Z; Shankaran P; Madlenakova M; Bodor J
Folia Microbiol (Praha); 2017 Jan; 62(1):73-87. PubMed ID: 27709447
[TBL] [Abstract][Full Text] [Related]
11. Immunological strategies to target HIV persistence.
Martrus G; Altfeld M
Curr Opin HIV AIDS; 2016 Jul; 11(4):402-8. PubMed ID: 27054281
[TBL] [Abstract][Full Text] [Related]
12. HIV reservoirs as obstacles and opportunities for an HIV cure.
Chun TW; Moir S; Fauci AS
Nat Immunol; 2015 Jun; 16(6):584-9. PubMed ID: 25990814
[TBL] [Abstract][Full Text] [Related]
13. Which therapeutic strategy will achieve a cure for HIV-1?
Cillo AR; Mellors JW
Curr Opin Virol; 2016 Jun; 18():14-9. PubMed ID: 26985878
[TBL] [Abstract][Full Text] [Related]
14. The challenge of finding a cure for HIV infection.
Richman DD; Margolis DM; Delaney M; Greene WC; Hazuda D; Pomerantz RJ
Science; 2009 Mar; 323(5919):1304-7. PubMed ID: 19265012
[TBL] [Abstract][Full Text] [Related]
15. Towards HIV-1 remission: potential roles for broadly neutralizing antibodies.
Halper-Stromberg A; Nussenzweig MC
J Clin Invest; 2016 Feb; 126(2):415-23. PubMed ID: 26752643
[TBL] [Abstract][Full Text] [Related]
16. The thioacetate-ω(γ-lactam carboxamide) HDAC inhibitor ST7612AA1 as HIV-1 latency reactivation agent.
Badia R; Grau J; Riveira-Muñoz E; Ballana E; Giannini G; Esté JA
Antiviral Res; 2015 Nov; 123():62-9. PubMed ID: 26348004
[TBL] [Abstract][Full Text] [Related]
17. Beyond antiretroviral therapy: early interventions to control HIV-1 infection.
Gunst JD; Tolstrup M; Søgaard OS
AIDS; 2017 Jul; 31(12):1665-1667. PubMed ID: 28463884
[No Abstract] [Full Text] [Related]
18. 30 years after HIV identification: where to from here?
Stover J
Expert Rev Anti Infect Ther; 2011 Nov; 9(11):947-9. PubMed ID: 22029511
[No Abstract] [Full Text] [Related]
19. Modeling the timing of antilatency drug administration during HIV treatment.
Petravic J; Martyushev A; Reece JC; Kent SJ; Davenport MP
J Virol; 2014 Dec; 88(24):14050-6. PubMed ID: 25253352
[TBL] [Abstract][Full Text] [Related]
20. Novel histone deacetylase inhibitors CG05 and CG06 effectively reactivate latently infected HIV-1.
Choi BS; Lee HS; Oh YT; Hyun YL; Ro S; Kim SS; Hong KJ
AIDS; 2010 Feb; 24(4):609-11. PubMed ID: 20154582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
